Recombinant human lactoferrin lysozyme(Healthgen Biotechnology)

重组人乳铁蛋白溶菌酶（禾元生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human lactoferrin lysozyme(Healthgen Biotechnology)
Drug Alias NameHY1002
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionBacterial polysaccharides inhibitorsCell wall inhibitors
TargetsBacterial polysaccharides
Therapy Area/IndicationsDiarrheaRotavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuhan Healthgen Biotechnology Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Healthgen Biotechnology Corp
Inactive CompaniesN/A
Active IndicationsDiarrheaRotavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A